Biodesix Stock Up Over 90% In Three Months, Hits New 52-Week High

Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere

TSMC reported September revenue of NT$511.86 billion ($16.03 billion), up 54.6% year-over-year, driven by AI chip demand. The stock fell 1.35% ahead of the data. TSMC uses ASML's advanced lithography machines and will report Q3 earnings next week.

Lululemon (LULU) reported a 4% decline in Q2 revenue, driven by an 8% drop in Americas sales. International revenue rose 4%, but same-store sales fell 3%. The stock has fallen 55% year-to-date, with mixed retail investor sentiment on Stocktwits.

Applied Digital Corp (APLD) reported Q1 2027 revenue growth of 322% but a net loss of $221M. The company has $6.4B in debt and high stock-based compensation expenses. CEO Wes Cummins highlighted strong demand, premium pricing for leases, and expansion plans in Finland and North Dakota. The company is also focusing on mitigating supply chain constraints and adapting to changing customer workloads.